Zacks Investment Research downgraded shares of MEDICIS PHARM-A (MRX) from NEUTRAL to UNDERPERFORM on November 16, 2012, with a target price of $40.80.
Medicis is an independent pharmaceutical company focusing exclusively on the treatment of dermatological conditions. Medicis offers prescription, over-the-counter and physician-dispensed dermatology products, emphasizing the clinical effectiveness, quality, affordability and cosmetic elegance of its products. Medicis has achieved a leading position in branded products for the treatment of acne, acne-related conditions, psoriatic conditions and pruritic conditions, while also offering the leading over-the-counter topical analgesic and fade cream product in the U.S.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MEDICIS PHARM-A (MRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment